Core Viewpoint - 2025 is a pivotal year for the Chinese securities industry, focusing on deepening functional positioning and high-quality development, with an emphasis on mergers and acquisitions, international expansion, and technological innovation, particularly through AI applications [1][2]. Mergers and Acquisitions - The year marks a critical phase for mergers and acquisitions in the securities industry, with major firms like Guotai Junan and Haitong Securities merging to form Guotai Haitong Securities, and other significant consolidations such as Guolian Securities and Minsheng Securities [3][4]. - The competitive landscape is shifting, with Guotai Haitong leading in net profit, and Guolian Minsheng's ranking improving significantly from around 40th to the top 20 [3]. - New merger cases are emerging, such as CICC's plan to merge with Xinda Securities and Dongxing Securities, potentially creating a new entity with over 1 trillion yuan in total assets [3]. Industry Integration Logic - Two main integration strategies are evident: resource consolidation under the same actual controller and market-driven mergers aimed at enhancing national influence [4]. - Analysts suggest that resource integration may become the most important way for securities firms to quickly enhance scale and comprehensive strength [4]. Classification Evaluation Reform - A significant revision of the classification evaluation for securities firms is underway, emphasizing the need for firms to enhance their functional roles and professional capabilities [5][6]. - The new regulations aim to shift focus from revenue expansion to improving operational efficiency and professional skills, thereby enhancing overall industry competitiveness [5]. Margin Trading Market - The margin trading market is heating up, with a record balance of 2.54 trillion yuan, reflecting a 36.6% increase from the beginning of the year [7]. - Several firms have raised their margin trading limits, and a price war on interest rates has begun, with some firms offering rates below 4% [8][9]. Investment Banking and Technology - The securities industry is adapting to a new era of "hard technology," with reforms aimed at providing more inclusive financing paths for tech companies [10][11]. - Securities firms are establishing research institutes focused on emerging industries and enhancing their service capabilities through collaboration and talent development [11]. AI Integration - The adoption of AI technologies is rapidly transforming the industry, with applications expanding across various business functions, significantly improving efficiency [12][13]. - Firms are moving towards an "AI-native" model, enhancing client engagement and operational management through AI tools [12]. Internationalization of Securities Firms - The internationalization of Chinese securities firms is accelerating, with a focus on comprehensive service capabilities and participation in global market competition [14][15]. - This trend is driven by the growing demand for cross-border services and the strategic goal of building first-class investment banks [14]. Asset Management Transformation - The public offering process for asset management is at a turning point, with firms reassessing their positioning in the broader asset management landscape [16][17]. - The industry is witnessing a decline in the rush for public fund licenses, with many firms withdrawing applications, indicating a shift in focus towards existing business optimization [16]. Impact of Fund Fee Reforms - The implementation of public fund fee reforms is pushing securities firms to enhance their research and wealth management capabilities, with a notable decline in commission revenues [18]. - Firms are transitioning towards a buyer advisory model, focusing on asset management and providing comprehensive solutions rather than merely selling products [18]. Regulatory Environment - Regulatory signals indicate a potential easing of capital requirements for high-quality institutions, aimed at improving capital utilization efficiency [19]. - Analysts suggest that enhancing leverage and capital efficiency could drive growth in high-value capital-intensive businesses [19]. Name Changes Reflecting Strategic Shifts - A wave of name changes among securities firms signifies strategic realignments and resource restructuring following mergers and acquisitions [20][21]. - These changes reflect deeper integration and the influence of new stakeholders, indicating a shift in strategic focus and operational capabilities [20].

Core Viewpoint - Dongfang Securities predicts that the earnings per share of Gree Pharmaceutical-B (01672) will be -0.32, -0.35, and -0.38 HKD for the years 2025 to 2027, respectively, and estimates the company's fair market value at 18.366 billion HKD, corresponding to a target price of 18.38 HKD, initiating a "Buy" rating [1] Group 1: Weight Loss Market Potential - The prevalence of overweight or obesity is rapidly increasing, expected to affect nearly 3 billion people globally by 2030 [2] - Current weight loss drugs, primarily GLP-1 drugs, have low clinical usage rates, poor adherence, and significant weight rebound after discontinuation, indicating a need for improved options [2] - Real-world research suggests that more accessible, safer, and convenient GLP-1 drugs with longer dosing intervals could enhance usage rates and adherence, with oral, ultra-long-acting, and fat-loss-preserving drugs identified as promising directions [2] Group 2: Competitive Advantages of ASC30 - GLP-1 oral small molecules, such as ASC30, have multiple advantages over peptide-based drugs, with Eli Lilly's Orforglipron being the only oral small molecule to successfully complete Phase III clinical trials [3] - ASC30 is in the second tier of global development, showing stronger agonistic activity and higher exposure levels compared to Orfor, with optimal weight loss data and notable safety advantages in U.S. Phase I and II trials [3] - The increasing demand for business development (BD) opportunities in oral small molecules, especially after Orfor's Phase III results fell short of expectations, enhances ASC30's potential [3] Group 3: ASC47 and New Pipeline Developments - ASC47, a unique THRβ agonist, is part of the fat-loss-preserving pipeline, with the fastest progress seen in Eli Lilly's Bimagrumab, which shows improved weight loss effects when combined with semaglutide [4] - ASC47 demonstrated significantly enhanced weight loss effects in Phase I trials when combined with semaglutide, with a lower incidence of gastrointestinal adverse reactions and improved blood lipid profiles [4] - Since October 2025, the company has accelerated the clinical advancement of four new pipelines, including oral multi-target peptides and monthly subcutaneous injections, aiming to complete mainstream targets and report preliminary clinical data by the end of 2026 [4]

Core Viewpoint - The report from Dongfang Securities predicts that the earnings per share for Gree Pharmaceutical-B (01672) will be -0.32, -0.35, and -0.38 HKD for the years 2025 to 2027, respectively, and estimates the company's fair market value at 18.366 billion HKD, leading to a target price of 18.38 HKD, with an initial "Buy" rating assigned [1] Group 1: Weight Loss Market Potential - The prevalence of overweight and obesity is rapidly increasing, expected to affect nearly 3 billion people globally by 2030 [1] - Current weight loss drugs, primarily GLP-1 medications, have low clinical usage rates, poor adherence, and significant weight rebound after discontinuation [1] - Real-world research indicates that more accessible, safer, and more convenient GLP-1 drugs with longer dosing intervals could enhance usage rates and adherence, with oral, ultra-long-acting, and fat-loss-preserving medications identified as promising directions [1] Group 2: Competitive Advantages of ASC30 - The oral small molecule GLP-1, Orforglipron (Orfor) from Eli Lilly, is currently the only oral small molecule to have successfully completed Phase III clinical trials [2] - ASC30, developed by the company, is in the second tier of global development and shows stronger agonistic activity and higher exposure levels compared to Orfor, with superior weight loss data and safety in U.S. Phase I and II trials [2] - The increasing demand for business development (BD) opportunities in oral small molecules is noted, especially after Orfor's Phase III results fell short of expectations, enhancing ASC30's potential [2] Group 3: ASC47 for Fat Loss and Muscle Preservation - The pipeline for fat loss and muscle preservation includes Bimagrumab (Bima) from Eli Lilly, which shows the fastest progress, while ASC47 is the only THRβ agonist [3] - Phase II clinical results indicate that Bima combined with semaglutide (Semag) improves weight loss outcomes but has safety concerns such as muscle cramps [3] - ASC47 has demonstrated significantly improved weight loss effects when combined with Semag in Phase I trials, with a lower incidence of gastrointestinal adverse reactions and improved blood lipid profiles, positioning it as a safer fat loss and muscle preservation drug [3]

Group 1 - The announcement states that from December 30, 2025, Dongfang Securities Co., Ltd. will be added as a liquidity service provider for several ETFs managed by the company, including the ChiNext 50 ETF and ChiNext Enhanced ETF [1] Group 2 - The company will suspend subscription, redemption, conversion, and regular investment services for the Jiashan Tongzhou Bond Fund and Jiashan Xinrong Mixed Fund on December 31, 2025, with services resuming on January 5, 2026 [2][3] - The Jiashan Global Industry Upgrade Equity Fund will also suspend similar services on December 31, 2025, with a resumption date of January 5, 2026 [4] - The Jiashan Hengzhi Hong Kong Stock Connect ETF will suspend subscription and redemption services on December 31, 2025, but secondary market trading will still be available [7][12]

Core Viewpoint - The integration of technology empowerment and cultural soft power is becoming a new engine for the high-quality development of the securities industry, as emphasized by the leadership of Dongfang Securities [1]. Group 1: Digital Transformation and Cultural Integration - The digital transformation of securities companies is not only a technical upgrade but also an opportunity to reshape corporate culture, embedding cultural values into business processes [2]. - Dongfang Securities aims to create a digital culture that fosters agile response, open innovation, and efficient collaboration, which are essential soft powers for adapting to the new competitive landscape [2]. - The company is committed to enhancing its compliance management through digital means, including the development of a dynamic compliance monitoring system and intelligent compliance analysis tools [3]. Group 2: Risk Management and Compliance - Dongfang Securities is advancing its risk management system towards a digital and intelligent evolution, utilizing big data and AI to build a unified risk control platform [3]. - The company has developed a credit risk data system covering over 7,000 effective market entities, supporting various business types and enhancing risk measurement capabilities [3]. Group 3: Customer-Centric Services - The company is enhancing its core value of "customer-centric" by integrating it into its digital DNA, improving service temperature and precision through technology [4]. - Dongfang Securities has upgraded its "Dongfang Winner" app, achieving over 97% online business processing rate and significantly improving efficiency in the account opening process [4][6]. - The company has developed a multi-layered trading service system to meet diverse customer needs, including the "Dongfang Yuyun Rapid Trading System" for institutional investors [5]. Group 4: Organizational Innovation and Collaboration - Dongfang Securities is breaking down organizational barriers through technology, fostering a collaborative system that promotes resource sharing and process integration [6][7]. - The company is enhancing its "three investment linkage" mechanism to strengthen industry thinking and value discovery capabilities, focusing on hard technology and green finance [7]. Group 5: Future Opportunities and Challenges - The securities industry is facing significant opportunities and challenges as the Chinese bond market exceeds 130 trillion yuan and capital market reforms deepen [9]. - Dongfang Securities emphasizes the need for a dual-spiral strategy of "technology + culture" to ensure sustainable development and high-quality growth in the industry [9].

因第四届董事会任期届满，根据本公司章程有关规定，经本公司股东东方证券股份有限公司研究决定， 委派杨斌先生、成飞先生、尤文杰先生、张云先生、王峰先生担任公司第五届董事会董事，同意彭卫东 先生、杨勤法先生、赵子夜先生担任公司第五届董事会独立董事。其中赵子夜先生为新任独立董事，原 第四届董事会成员郭晔女士不再担任本公司独立董事。 公告送出日期：2025年12月27日 上海东方证券资产管理有限公司（以下简称"本公司"）的董事在最近12个月内变更超过百分之五十，根 据《公开募集证券投资基金信息披露管理办法》相关规定，现公告如下： 经本公司股东东方证券股份有限公司研究决定，张云、王峰先生自2025年4月3日起担任公司董事，蒋鹤 磊、张锋先生不再担任公司董事职务。 经本公司股东东方证券股份有限公司研究决定，成飞先生自2025年5月9日起担任公司董事。 经本公司第三届第六次职工代表大会决议，周代希先生自2025年6月25日起担任公司职工董事。 登录新浪财经APP 搜索【信披】查看更多考评等级 上述董事变更事项符合法律法规及本公司章程的有关规定，本公司将按规定报监管机构备案。 特此公告。 上海东方证券资产管理有限公司 2025 ...

Group 1 - The core viewpoint of the article is that the strategic cooperation between Jerry Holdings and Kawasaki is expected to enhance the certainty of Jerry's power generation business and expand its overseas market opportunities [1] - The partnership will supplement Jerry's gas turbine supply, providing support for its power generation business and increasing the certainty of its data center power generation operations [1] - Jerry has already made breakthroughs in the North American data center power supply sector, demonstrating strong international development potential with replicable and scalable application results [1] Group 2 - The cooperation is global in scope, which is anticipated to support Jerry's data center power generation business outside the United States and further open up its overseas business space [1] - The profit forecast for Jerry is maintained, with projected net profits attributable to shareholders for 2025, 2026, and 2027 being 3.153 billion, 3.818 billion, and 4.464 billion yuan respectively [1] - Based on comparable company valuations, a target price of 74.6 yuan is set for the company, maintaining a "buy" rating with a 20x PE for 2026 [1]

东方证券发布研报称，2026年铜精矿长单加工费归零，凸显铜矿供给与冶炼端结构性矛盾。传统需求筑 底叠加新兴领域强劲增长，矿端供不应求局面或将延续，支撑铜价中枢。中期随大型矿山复产及国内冶 炼行业调整，加工费或存边际改善空间。建议关注资源型矿企与自给率提升的冶炼龙头。 东方证券主要观点如下： 尽管中期铜精矿供小于求局面或不改，但从边际角度来看供给端与冶炼端供需矛盾或有改善潜力。当前 全球第二大铜矿Grasberg已宣布重启和复产计划，产量有望在26-27年持续增长，可供应全球约1.5%铜 矿产量的第一量子旗下Cobre Panamá铜矿的重启谈判也有望于26年初开启。该行认为，在中期矿端干扰 被逐渐排除的情况下，如Grasberg、Cobre Panamá等铜矿的重新恢复正常生产或将显著贡献矿端增量， 从而缓和铜矿供给与铜冶炼之间的供需矛盾，叠加国内铜冶炼"反内卷"措施出台落地的预期，铜精矿现 货加工费有望向上改善。该行看好铜冶炼企业在缓和预期下盈利改善的潜力，继续看好中期矿价与冶炼 费边际同涨。 投资建议与投资标的 铜矿端：建议关注资源储量较大、中期铜矿持续扩产存在增量预期的紫金矿业（601899） (601 ...

Group 1 - The core viewpoint of the news is that Dongfang Securities has shown a positive stock performance with a 6.85% increase year-to-date and a market capitalization of 938.88 billion yuan as of December 26 [1] - As of December 26, Dongfang Securities' stock price reached 11.05 yuan per share, with a trading volume of 2.88 billion yuan and a turnover rate of 0.35% [1] - The net inflow of main funds was 310.95 million yuan, with significant buying and selling activities observed in large orders [1] Group 2 - Dongfang Securities, established on December 10, 1997, is located in Shanghai and was listed on March 23, 2015. Its main business includes securities brokerage, investment banking, asset management, and other financial services [2] - The revenue composition of Dongfang Securities includes 39.93% from institutional and sales trading, 32.07% from wealth and asset management, 15.73% from international business and others, and 12.46% from investment banking and alternative investments [2] - As of September 30, 2025, Dongfang Securities reported a revenue of 12.708 billion yuan, a year-on-year decrease of 9.74%, while the net profit attributable to shareholders increased by 54.76% to 5.110 billion yuan [2] Group 3 - Dongfang Securities has distributed a total of 16.155 billion yuan in dividends since its A-share listing, with 5.034 billion yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation and Hong Kong Central Clearing Limited, with notable changes in their holdings [3]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：进门聊 责任编辑：何俊熹 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：进门聊 责任编辑：何俊熹 ...